MAJIC-PV: Clinical Implications in PV

The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.

Ropeginterferon alfa-2b has been approved by Health Canada for the treatment of adult patients with polycythemia vera.

Long-term follow-up from the REVIVE and THRIVE studies showed a low thromboembolic event rate with rusfertide in phlebotomy-dependent polycythemia vera.

The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.

Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.

Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.

Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.